
Savara (SVRA) Stock Forecast & Price Target
Savara (SVRA) Analyst Ratings
Bulls say
Savara Inc. is experiencing a positive outlook due to a recent increase in estimated peak annual sales for its molgramostim nebulizer solution, now projected at $962 million compared to prior estimates of $680 million. The company's management has provided updated pricing estimates, anticipating a list price for Molbreevi in the range of $400,000 to $500,000, leading to an increased launch price estimate of $425,000. These developments, along with a consistent stream of positive updates, have prompted analysts to revise their discounted cash flow-derived price target for Savara shares upwards to $11.
Bears say
Savara Inc. faces a challenging outlook due to potential delays in regulatory approval for its molgramostim nebulizer solution, which could severely hinder market entry and, consequently, sales and market share. The company also reported higher-than-anticipated research and development (R&D) and selling, general, and administrative (SG&A) expenses, coupled with lower total other income, which negatively affects its financial health. Furthermore, there has been a decrease in projected peak market penetration rates, indicating potential difficulties in achieving growth targets.
This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.
Savara (SVRA) Analyst Forecast & Price Prediction
Start investing in Savara (SVRA)
Order type
Buy in
Order amount
Est. shares
0 shares